Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336548 | 0.88 | MAPK1 (0.54) | MAPK1MEN1KMT2AMAPTATM | |
| SCHEMBL29215638 | 0.87 | USP2 (0.43) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL21963889 | 0.87 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16986998 | 0.87 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL20475488 | 0.86 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL22018261 | 0.85 | PKM (0.46) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL5895249 | 0.85 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL2467764 | 0.84 | CYP4F2 (0.52) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL4295685 | 0.84 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL3970403 | 0.84 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880308-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| EP-1973914-A2 | TRANSFORMING GROWTH FACTOR MODULATORS | Biogen Idec MA Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007076086-A2 | TRICYCLIC SPIRO COMPOUNDS USEFUL AS TRANSFORMING GROWTH FACTOR MODULATORS | BIOGEN IDEC MA INC (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | PKM 2507/4885USP2 4117/4885SMN1; SMN2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.